15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $9.9B | $1.3B | 75.7% | 0.0% | $2.1B | $6.3B | $3.0B |
| 2024 | $9.7B | $1.6B | 76.1% | 0.0% | $2.7B | $4.5B | $2.4B |
| 2023 | $9.8B | $1.2B | 74.2% | 0.0% | $1.3B | $6.8B | $1.0B |
| 2022 | $10.2B | $3.0B | 77.6% | 0.0% | $1.1B | $6.3B | $3.4B |
| 2021 | $11.0B | $1.6B | 80.8% | 25.9% | $3.4B | $6.3B | $2.3B |
| 2020 | $13.4B | $4.0B | 86.6% | 33.8% | $3.8B | $7.4B | $1.3B |
| 2019 | $14.4B | $5.9B | 86.4% | 49.0% | $6.6B | $4.5B | $2.9B |
| 2018 | $13.5B | $4.4B | 86.5% | 43.8% | $5.4B | $5.9B | $1.2B |
| 2017 | $12.3B | $2.5B | 86.7% | 43.6% | $3.7B | $5.9B | $1.6B |
| 2016 | $11.4B | $3.7B | 87.1% | 45.0% | $4.0B | $6.5B | — |
| 2015 | $10.8B | $3.5B | 88.5% | 45.4% | $3.3B | $6.5B | — |
| 2014 | $9.7B | $2.9B | 87.9% | 40.9% | $2.7B | $580M | — |
| 2013 | $6.9B | $1.9B | 87.6% | 36.3% | $2.1B | $592M | — |
| 2012 | $5.5B | $1.4B | 90.1% | 33.6% | $1.6B | $687M | — |
| 2011 | $5.0B | $1.2B | 90.8% | 34.2% | $1.5B | $1.0B | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2.5B | $320M | 73.3% | 0.0% | $594M | $6.3B | $3.4B |
| Dec '25 | $2.3B | -$49M | 78.3% | 0.0% | $468M | $6.3B | $3.0B |
| Sep '25 | $2.5B | $467M | 73.4% | 0.0% | $1.2B | $6.3B | $3.9B |
| Jun '25 | $2.6B | $635M | 77.1% | 0.0% | $134M | $6.3B | $2.8B |
| Mar '25 | $2.4B | $241M | 74.1% | 0.0% | $222M | $4.5B | $2.6B |
| Dec '24 | $2.5B | $267M | 76.2% | 0.0% | $722M | $4.5B | $2.4B |
| Sep '24 | $2.5B | $389M | 74.1% | 0.0% | $901M | $4.5B | $1.7B |
| Jun '24 | $2.5B | $584M | 77.8% | 0.0% | $592M | $6.3B | $1.9B |
| Mar '24 | $2.3B | $393M | 76.3% | 0.0% | $507M | $6.3B | $1.1B |
| Dec '23 | $2.4B | $250M | 74.1% | 0.0% | -$53M | $6.8B | $1.0B |
| Sep '23 | $2.5B | -$68M | 73.9% | 0.0% | $518M | $6.8B | $2.3B |
| Jun '23 | $2.5B | $592M | 75.9% | 0.0% | $416M | $6.3B | $2.6B |
| Mar '23 | $2.5B | $388M | 73.1% | 0.0% | $389M | $6.3B | $2.9B |
| Dec '22 | $2.5B | $550M | 77.6% | 0.0% | -$261M | $6.3B | $3.4B |
| Sep '22 | $2.5B | $1.1B | 81.3% | 0.0% | $602M | $6.3B | $3.7B |
| Jun '22 | $2.6B | $1.1B | 81.3% | 0.0% | $700M | $6.3B | $2.6B |
| Mar '22 | $2.5B | $304M | 70.2% | 24.1% | $104M | $6.3B | $1.7B |
| Dec '21 | $2.7B | $368M | 75.9% | 21.5% | $787M | $6.3B | $2.3B |
| Sep '21 | $2.8B | $329M | 81.6% | 28.6% | $763M | $6.3B | $1.5B |
| Jun '21 | $2.8B | $449M | 83.4% | 17.5% | $1.2B | $7.3B | $1.7B |
How the market has priced BIIB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Biogen's revenue has declined 6.0% per year, and net income declined 20.2% per year. These are computed facts, not advice.
As of FY2025, Biogen reported $6.3B of total debt against $3.0B of cash.
In FY2025, gross margin was 75.7%, operating margin —, and net margin 13.1%.
As of Jun '26, Biogen traded at a price-to-earnings ratio of about 23.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.